Abstract

 
 
 Chronic heart failure (CHF) is a global public health problem. Despite all the technical advances available in modern cardiology, a medical strategy for the treatment of CHF has been and remains the main focus of therapeutic intervention. А particular problem is the treatment of CHF with concomitant pathology. The modern pharmacological strategy for the treatment of patients with CHF and iron deficiency anemia, except iron preparations, must take into account the use of agents that have antihypoxic, antioxidant and membrane-stabilizing effects, and at the same time regulatory effect on the metabolism of physiologically active compounds to improve the condition of patients. Therefore, this study is aimed to evaluate the effectiveness of iron deficiency anemia’s correction, identify and compare the effect of oral ferrotherapy and combined use of ferrotherapy with L-carnitine on clinical and instrumental parameters of patients with chronic heart failure with reduced ejection fraction of left ventricle as possible variants of additional therapy to standard treatment.
 
 
Highlights
Chronic heart failure (CHF) with reduced left ventricular (LV) ejection fraction (EF) is a clinical syndrome of dyspnea, exercise intolerance and/or edema resulting from an impairment of ejection of blood, usually documented by a left ventricular ejection fraction of 40% or less on echocardiography [1]
The incidence of anemia appears to grow with increase in functional class (FC) of chronic heart failure according to NYHA classification – at FC III to 33% and at FC IV to 80% [3, 4]
The purpose of the study is to evaluate the effectiveness of IDA correction, identify and compare the effect of oral ferrotherapy and combined use of ferrotherapy with L-carnitine on clinical and instrumental parameters of patients with CHF with reduced LVEF as possible variants additional therapy to standard treatment
Summary
Chronic heart failure (CHF) with reduced left ventricular (LV) ejection fraction (EF) is a clinical syndrome of dyspnea, exercise intolerance and/or edema resulting from an impairment of ejection of blood, usually documented by a left ventricular ejection fraction of 40% or less on echocardiography [1]. An important clinical aspect is that iron deficiency anemia (IDА), except sideropenic syndrome, manifests with nonspecific symptoms. Symptoms such as dyspnea and fatigue may be difficult to distinguish from symptoms of HF. It can be diagnosed only by determining the laboratory parameters while the anemia syndrome during CHF is associated with an increase in mortality and the frequency of hospitalizations of patients [5, 6, 7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
